Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy

Journal of Clinical Virology

Volumn 49, Issue 1, 2010, Pages 32-36

  Buyck, Hubertus C E ^a,b   Griffiths, Paul D ^a   Emery, Vincent C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ganciclovir; HCMV disease; HCMV load

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; VALGANCICLOVIR;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; STEM CELL; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION;

EID: 77955661053     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.06.018     Document Type: Article

References (39)

1. Cope A.V., Sabin C., Burroughs A., Rolles K., Griffiths P.D., Emery V.C., et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997, 176:1484-1490.
2. Emery V.C., Cope A.V., Sabin C.A., Burroughs A.K., Rolles K., Lazzarotto T., et al. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. J Infect Dis 2000, 182:1610-1615.
3. Hassan-Walker A.F., Kidd I.M., Sabin C., Sweny P., Griffiths P.D., Emery V.C., et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999, 58:182-187.
4. Mendez J., Espy M., Smith T.F., Wilson J., Wiesner R., Paya C.V. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998, 65:1477-1481.
5. Regoes R.R., Bowen E.F., Cope A.V., Gor D., Hassan-Walker A.F., Prentice H.G., et al. Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc Biol Sci 2006, 273:1961-1967.
6. Gor D., Sabin C., Prentice H.G., Vyas N., Man S., Griffiths P.D., et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21:597-605.
7. Humar A., Gregson D., Caliendo A.M., McGeer A., Malkan G., Krajden M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68:1305-1311.
8. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190:177-182.
9. Emery V.C., Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000, 97:8039-8044.
10. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997, 350:1729-1733.
11. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611-620.
12. Winston D.J., Wirin D., Shaked A., Busuttil R.W. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995, 346:69-74.
13. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
14. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
15. Ljungman P., De la Camara R., Milpied N., Volin L., Russell C.A., Crisp A., et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002, 99:3050-3056.
16. Meyers J.D., Reed E.C., Shepp D.H., Thornquist M., Dandliker P.S., Vicary C.A., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988, 318:70-75.
17. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N., Fernandez Rañada J.M., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994, 343:749-753.
18. Griffiths P.D., Feinberg J.E., Fry J., Sabin C., Dix L., Gor D., et al. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency disease. J Infec Dis 1998, 177:57-64.
19. Emery V.C., Sabin C.A., Feinberg J.E., Grywacz M., Knight S., Griffiths P.D. Quantitative effects of valaciclovir on the replication of cytomegalovirus in patients with advanced human immunodeficiency virus disease: baseline cytomegaloviral load dictates time to disease and survival. J Infec Dis 1999, 180:695-701.
20. Ayala E., Greene J., Sandin R., Perkins J., Field T., Tate C., et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 37:851-856.
21. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
22. Nakamura R., Cortez K., Solomon S., Battiwalla M., Gill V.J., Hensel N., et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:235-242.
23. Asberg A., Humar A., Rollag H., Jardine A.G., Mouas H., Pescovitz M.D., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7:2106-2113.
24. van der Heiden P.L., Kalpoe J.S., Barge R.M., Willemze R., Kroes A.C., Schippers E.F., et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006, 37:693-698.
25. Gerna G., Lilleri D., Zecca M., Alessandrino E.P., Baldanti F., Revello M.G., et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005, 90:526-533.
26. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M., et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97:867-874.
27. Humar A., Kumar D., Boivin G., Caliendo A.M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002, 186:829-833.
28. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., Burroughs A.K., Sweny P., Griffiths P.D., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191:89-92.
29. Bowen E.F., Wilson P., Cope A., Sabin C., Griffiths P., Davey C., et al. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 1996, 10:1515-1520.
30. Spector S.A., Wong R., Hsia K., Pilcher M., Stempien M.J. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998, 101:497-502.
31. Emery V.C., Hassan-Walker A.F., Burroughs A.K., Griffiths P.D. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002, 185:1723-1728.
32. Tormo N., Solano C., Benet I., Clari M.A., Nieto J., de la Cámara R., et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8(+) and CD4(+) T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2010, 45:543-549.
33. Grob J.P., Grundy J.E., Prentice H.G., Griffiths P.D., Hoffbrand A.V., Hughes M.D., et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987, 1:774-776.
34. Ljungman P., Perez-Bercoff L., Jonsson J., Avetisyan G., Sparrelid E., Aschan J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
35. Sia I.G., Wilson J.A., Groettum C.M., Espy M.J., Smith T.F., Paya C.V. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000, 181:717-720.
36. Mattes F.M., Hainsworth E.G., Geretti A.M., Nebbia G., Prentice G., Potter M., et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004, 189:1355-1361.
37. Morris E.C., Rebello P., Thomson K.J., Peggs K.S., Kyriakou C., Goldstone A.H., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:4-406.
38. Chakrabarti S., Mackinnon S., Chopra R., Kottaridis P.D., Peggs K., O'Gorman P., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
39. Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93:248-256.